Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Facet Biotech to axe 80 jobs
While the workforce reductions will take place across the organization, the company will maintain core competencies in the research, development and product operations areas in order to support
While the workforce reductions will take place across the organization, the company will maintain core competencies in the research, development and product operations areas in order to support
The FDA 510(k) clearance has been granted based on its premarket notification for indications for the use of elevating tissue temperature and temporary relief of muscle and joint
Lilly is continuing to work with the agency on the new drug application (NDA). The FDA does not require any additional clinical trials for the continued review of
Proceeds from the financing will be used to accelerate development of Atrimers, a new class of protein therapeutics that the company is developing to address significant unmet medical
His resignation, effective January 9, 2009, follows an 11-year career with Acusphere, in which he oversaw the company’s clinical trials for its lead product candidate, Imagify for injectable
Numoda is currently managing Columbia’s ongoing Pregnant study of Prochieve 8% (progesterone gel) to reduce the risk of preterm birth in women with a short cervix at mid-pregnancy.
KMD-3213 is a selective alpha 1A-adrenoceptor antagonist originally discovered by Kissei Pharmaceutical Co. It was developed by Daiichi Sankyo and Kissei Pharmaceutical and is jointly marketed as Urief
Mr Howard joins MDS Pharma Services from his private consulting practice where he offered business and financial consulting services, including merger and acquisition services, for clients across a
Under the agreement, Teva would be using the Codexis process for key process steps in the manufacture of this product, assuming technical milestones are met. Financial terms were
“This is yet another important step in Rosetta Genomics’ commercialization efforts,” noted Ronen Tamir, Chief Commercialization Officer at Rosetta Genomics. “As Israel provided its citizens with health insurance